As of Oct 27
| +0.25 / +0.82%|
The 8 analysts offering 12-month price forecasts for Clovis Oncology Inc have a median target of 38.50, with a high estimate of 50.00 and a low estimate of 12.00. The median estimate represents a +24.72% increase from the last price of 30.87.
The current consensus among 8 polled investment analysts is to Hold stock in Clovis Oncology Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.